Marc De Hert, MD, PhD

Topiramate-Antipsychotic Cotreatment

June 22, 2016

Topiramate is known to cause weight loss, but it's also known to cause adverse psychiatric side effects. So how would topiramate affect patients already taking antipsychotics? Read this meta-analysis...

Christoph U. Correll, Lawrence Maayan, John Kane, et al

Meta-Analysis

Prevalence and Predictors of Type 2 Diabetes Mellitus in People With Bipolar Disorder: A Systematic Review and Meta-Analysis

November 25, 2015

Davy Vancampfort, Alex J. Mitchell, Marc De Hert, et al

Original Research

Do Advanced Statistical Techniques Really Help in the Diagnosis of the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotics?

October 21, 2015

Jeroen Van Schependom, Weiping Yu, Jeroen Gielen, et al

Original Research

Prediabetes in Patients Treated With Antipsychotic Drugs

December 27, 2011

Peter Manu, Christoph U. Correll, Ruud van Winkel, et al

Article

Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent? A Literature Review

July 21, 2009

Viktoria Simon, Ruud van Winkel, Marc De Hert

Article

Psychiatric Diagnosis as an Independent Risk Factor for Metabolic Disturbances: Results From a Comprehensive, Naturalistic Screening Program

August 31, 2008

Ruud van Winkel, Jim van Os, Ivan Celic, et al

Original Research

Comorbid Somatic Illnesses in Patients With Severe Mental Disorders: Clinical, Policy, and Research Challenges

March 18, 2008

W. Wolfgang Fleischhacker, Marcelo Cetkovich-Bakmas, Marc De Hert, et al

Article

Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic Medication in Patients With Schizophrenia and Schizoaffective Disorder

March 14, 2008

Ruud van Winkel, Marc De Hert, Martien Wampers, et al

Letter to the Editor

Reply to Applicability of the Oral Glucose Tolerance Test in Assessing Prevalence and Incidence of Diabetes Mellitus in Schizophrenia

August 15, 2007

Ruud van Winkel, Marc De Hert

Original Research

Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder

December 15, 2006

Marc De Hert, Dita Kalnicka, Ruud van Winkel, et al

Original Research

Screening for Diabetes and Other Metabolic Abnormalities in Patients With Schizophrenia and Schizoaffective Disorder: Evaluation of Incidence and Screening Methods.

October 16, 2006

Ruud van Winkel, Marc De Hert, Dominique Van Eyck, et al

Topiramate-Antipsychotic Cotreatment

Prevalence and Predictors of Type 2 Diabetes Mellitus in People With Bipolar Disorder: A Systematic Review and Meta-Analysis

Do Advanced Statistical Techniques Really Help in the Diagnosis of the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotics?

Prediabetes in Patients Treated With Antipsychotic Drugs

Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent? A Literature Review

Psychiatric Diagnosis as an Independent Risk Factor for Metabolic Disturbances: Results From a Comprehensive, Naturalistic Screening Program

Comorbid Somatic Illnesses in Patients With Severe Mental Disorders: Clinical, Policy, and Research Challenges

Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic Medication in Patients With Schizophrenia and Schizoaffective Disorder

Reply to Applicability of the Oral Glucose Tolerance Test in Assessing Prevalence and Incidence of Diabetes Mellitus in Schizophrenia

Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder

Screening for Diabetes and Other Metabolic Abnormalities in Patients With Schizophrenia and Schizoaffective Disorder: Evaluation of Incidence and Screening Methods.

ELSEWHERE:

FOLLOW US:

Marc De Hert, MD, PhD

Topiramate-Antipsychotic Cotreatment

Prevalence and Predictors of Type 2 Diabetes Mellitus in People With Bipolar Disorder: A Systematic Review and Meta-Analysis

Do Advanced Statistical Techniques Really Help in the Diagnosis of the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotics?

Prediabetes in Patients Treated With Antipsychotic Drugs

Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent? A Literature Review

Psychiatric Diagnosis as an Independent Risk Factor for Metabolic Disturbances: Results From a Comprehensive, Naturalistic Screening Program

Comorbid Somatic Illnesses in Patients With Severe Mental Disorders: Clinical, Policy, and Research Challenges

Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic Medication in Patients With Schizophrenia and Schizoaffective Disorder

Reply to Applicability of the Oral Glucose Tolerance Test in Assessing Prevalence and Incidence of Diabetes Mellitus in Schizophrenia

Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder

Screening for Diabetes and Other Metabolic Abnormalities in Patients With Schizophrenia and Schizoaffective Disorder: Evaluation of Incidence and Screening Methods.

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles